The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...
Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
In their case-controlled study that utilized the National Inpatient Sample 2016-2019 database, researchers set out to examine the relationship between leukemia and sickle cell trait.
Researchers performed a retrospective observational study to determine whether DNA sequencing can detect residual disease in adults with acute myeloid leukemia (AML) in first remission.
Researchers reported on the treatment approaches and outcomes of patients with T‑cell prolymphocytic leukemia after allogeneic transplant in a multicenter, retrospective study.
Researchers set out to determine whether cancer-related cognitive impairment impacts older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy.
